Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, open-label, randomized controlled trial to compare the
efficacy of organoid-guided treatment (OGT) to treatment of physician's choice (TPC) in
previously treated, HER2-negative locally advanced or metastatic breast cancer. The study
will seek to provide evidence for utilizing patient-derived organoid (PDO) model to
personalize treatment strategies and inform clinical care for advanced breast cancer.
Subjects randomized to the OGT group will undergo PDO generation and receive treatment
dictated by subsequent PDO drug sensitivity screening. Subjects randomized to the TPC group
will receive empirical therapy as selected by the treating physician.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong Provincial People's Hospital
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University Shantou Central Hospital Sun Yat-sen University